このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

10x Genomics マネジメント

マネジメント基準チェック /34

10x Genomics'の CEO はSerge Saxonovで、 Jul2012年に任命され、の在任期間は 11.92年です。の年間総報酬は$ 8.29Mで、 6.6%給与と93.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.36%を直接所有しており、その価値は$ 80.30M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と6.8年です。

主要情報

Serge Saxonov

最高経営責任者

US$8.3m

報酬総額

CEO給与比率	6.6%
CEO在任期間	11.9yrs
CEOの所有権	3.4%
経営陣の平均在職期間	6.3yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

10x Genomics の収益と比較して、Serge Saxonov の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$264m
Dec 31 2023	US$8m	US$545k	-US$255m
Sep 30 2023	n/a	n/a	-US$223m
Jun 30 2023	n/a	n/a	-US$172m
Mar 31 2023	n/a	n/a	-US$174m
Dec 31 2022	US$19m	US$504k	-US$166m
Sep 30 2022	n/a	n/a	-US$167m
Jun 30 2022	n/a	n/a	-US$142m
Mar 31 2022	n/a	n/a	-US$89m
Dec 31 2021	US$12m	US$430k	-US$58m
Sep 30 2021	n/a	n/a	-US$455m
Jun 30 2021	n/a	n/a	-US$504m
Mar 31 2021	n/a	n/a	-US$533m
Dec 31 2020	US$11m	US$400k	-US$543m
Sep 30 2020	n/a	n/a	-US$134m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$2m	US$394k	-US$31m
Sep 30 2019	n/a	n/a	-US$100m
Jun 30 2019	n/a	n/a	-US$105m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$1m	US$366k	-US$112m

報酬と市場: Sergeの総報酬 ($USD 8.29M ) は、 UK市場 ($USD 2.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Sergeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Serge Saxonov (47 yo)

11.9yrs

在職期間

US$8,286,050

報酬

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Serge Saxonov	Co-Founder	11.9yrs	US$8.29m	3.36% $ 79.5m
Benjamin Hindson	Co-Founder	11.9yrs	US$4.43m	2.69% $ 63.8m
Justin McAnear	Chief Financial Officer	5.7yrs	US$3.31m	0.047% $ 1.1m
Eric Whitaker	Chief Legal Officer	6.9yrs	US$3.88m	0.12% $ 2.8m
Michael Schnall-Levin	Founding Scientist & CTO	2.4yrs	データなし	データなし
Cassie Corneau	Manager of Investor Relations and Strategic Finance	no data	データなし	データなし
Rebecca Port	Chief People Officer	3.4yrs	データなし	データなし
Jens Durruthy	Associate Director of Product Management	no data	データなし	データなし

6.3yrs

平均在職期間

48.5yo

平均年齢

経験豊富な経営陣: 0A88の経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Serge Saxonov	Co-Founder	11.9yrs	US$8.29m	3.36% $ 79.5m
Benjamin Hindson	Co-Founder	11.9yrs	US$4.43m	2.69% $ 63.8m
Kimberly Popovits	Independent Director	4.3yrs	US$338.71k	0.0039% $ 91.1k
John Stuelpnagel	Independent Chairman	10.8yrs	US$403.59k	2.04% $ 48.3m
Shehnaaz Suliman	Independent Director	4.8yrs	US$336.39k	0.0039% $ 91.1k
Mathai Mammen	Independent Director	6.8yrs	US$331.39k	0.14% $ 3.4m
Sridhar Kosaraju	Independent Director	5.2yrs	US$346.39k	0.030% $ 700.8k

6.8yrs

平均在職期間

52yo

平均年齢

経験豊富なボード: 0A88の取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

10x Genomics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

10x Genomics, Inc., Annual General Meeting, Jun 11, 2024

James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024

Chief Commercial Officer recently sold US$619k worth of stock

Chief Commercial Officer recently sold US$444k worth of stock

10X Genomics, Inc. Announces Board Changes

Independent Chairman recently sold US$549k worth of stock

Recent updates

10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium

10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.50 loss per share (vs US$0.44 loss in 1Q 2023)

10x Genomics, Inc., Annual General Meeting, Jun 11, 2024

10x Genomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay

10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products

Full year 2023 earnings released: US$2.18 loss per share (vs US$1.46 loss in FY 2022)

10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024

10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

10x Genomics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Chief Commercial Officer recently sold US$619k worth of stock

10X Genomics, Inc. Raises Revenue Guidance for Full Year 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$0.37 loss in 3Q 2022)

10X Genomics, Inc. Announces Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

New minor risk - Share price stability

10x Genomics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

10x Genomics, Inc. Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit

10X Genomics, Inc. Announces Use of Its Technologies in A Study Published in the Journal of Clinical Investment

Chief Commercial Officer recently sold US$444k worth of stock

10x Genomics, Inc. Raises Revenue Guidance for the Full Year 2023

Forecast to breakeven in 2025

Forecast to breakeven in 2025

10X Genomics, Inc. Announces Board Changes

10x Genomics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vizgen, Inc. Provides Update on Litigation

10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Index

Independent Chairman recently sold US$549k worth of stock

Co-Founder recently sold US$143k worth of stock

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2022)

No longer forecast to breakeven

10X Genomics, Inc. Revises Revenue Guidance for the Full Year 2023

Forecast to breakeven in 2025

Co-Founder recently sold US$93k worth of stock

Full year 2022 earnings released: US$1.46 loss per share (vs US$0.53 loss in FY 2021)

10x Genomics, Inc. Provides Revenue Guidance for the Full Year 2023

Now 21% undervalued

10x Genomics, Inc. to Report Q4, 2022 Results on Feb 15, 2023

10x Genomics, Inc. Launches Xenium Platform for In Situ Analysis

Co-Founder recently sold US$91k worth of stock

Insufficient new directors

10X Genomics, Inc. Announces Commercial Availability of BEAM

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.15 loss in 3Q 2021)

10X Genomics, Inc. Provides Revenue Guidance for Full Year 2022

10x Genomics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Insufficient new directors

Co-Founder recently sold US$96k worth of stock

No longer forecast to breakeven

10X Genomics, Inc. Provides Earnings Guidance for the Third Quarter of 2022 and Full Year 2022

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.10 loss in 2Q 2021)

Forecast breakeven date moved forward to 2023

10x Genomics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

10x Genomics Inc. Advances Leadership and Innovation in Single Cell and Spatial Technologies At 2022 AGBT General Meeting

Co-Founder recently sold US$130k worth of stock

First quarter 2022 earnings released: US$0.38 loss per share (vs US$0.11 loss in 1Q 2021)

10x Genomics, Inc. Maintains Revenue Guidance for Full Year 2022

10x Genomics, Inc., Annual General Meeting, Jun 15, 2022

Forecast breakeven date pushed back to 2024

10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium

10x Genomics, Inc. to Report Q1, 2022 Results on May 04, 2022

10X Genomics, Inc. Showcases Robust Innovation Pipeline at Xperience 2022 Event

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

10x Genomics, Inc. Provides Revenue Guidance for the Full Year of 2022

10X Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network

マネジメント基準チェック /34